Kisspeptin-10 Side Effects: What Studies and Users Report
What FDA labels and clinical studies report for Kisspeptin-10, how strong that evidence is, and what is still unknown.
Side effects reported in studies
Side effects reported in published studies, strongest design first. Frequencies are quoted as the source gives them; animal results are labelled.
| Side effect | How common | Study type | Source |
|---|---|---|---|
| Tolerability“Kisspeptin was well-tolerated with no reported adverse effects.” | Frequency not stated | Human RCTn = 40 | JAMA network open 2022, PMID 36287566 |
| Pituitary hormone safety check“Mean serum GH, PRL and TSH did not change during the first 4 h following kisspeptin-54 injection when compared with vehicle.” | Frequency not stated | Human controlled trialn = 5 | Clinical endocrinology 2014, PMID 24863252 |
| Adverse effects“No adverse effects were observed.” | Frequency not stated | Human RCT | Clinical pharmacology and therapeutics 2010, PMID 20980998 |
What is not known
- How common each effect is at the doses people use outside of studies.
- Effects that take longer to appear than the length of the published studies.
- How Kisspeptin-10 interacts with other medicines and supplements.
- Whether research-grade products, which are not checked by the FDA, behave like the material used in studies.
When to get medical help
This is not a complete list. A doctor or pharmacist can help you judge whether a symptom is related.
Common questions
What are the side effects of Kisspeptin-10?
Studies we summarise reported tolerability, pituitary hormone safety check, adverse effects. The table on this page gives how often each happened and links each source.
Is Kisspeptin-10 safe?
Kisspeptin-10 has an FDA-approved label that lists its known risks. That label covers the approved product used as prescribed, not compounded or research-chemical versions.
Is Kisspeptin-10 banned in sport?
Yes. Prohibited by WADA (S2.2.1). Tested athletes should not use it.
More on Kisspeptin-10
Sources
- 1Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial.JAMA network open · 2022PMID 36287566Accessed 2 Oct 2026
- 2Acute and chronic effects of kisspeptin-54 administration on GH, prolactin and TSH secretion in healthy women.Clinical endocrinology · 2014PMID 24863252Accessed 2 Oct 2026
- 3Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea.Clinical pharmacology and therapeutics · 2010PMID 20980998Accessed 2 Oct 2026
Found an error? Report a correction.